BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today presented positive data from its two completed, randomized, double-blind, placebo-controlled Phase 2 studies of BCX4208 in patients with gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, U.K. Stock of the company has jumped 8% in premarket trade
Biotech Breakfast: Biocryst Pharmaceuticals, Inc ( NASDAQ: BCRX ) presents positive data of BCX4208 a possible treatment of Gout.
0 comments